A phytochemical assessment of the antioxidant and cytotoxic properties of Helleborus odorus subsp. cyclophyllus extract

03:3911 months ago

Helleborus sp. is a member of the Ranunculaceae family, and are small, perennial herbs common in Central and Southern Europe and Asia. Their distribution in Europe elevated their position in therapeutic remedies since the ancient time and mythology. Due to their potent and rich extracts from their roots, hellebores have been used in traditional and folklore remedies as they present rich sources in glycosides. Mainly, these plants have exhibited cathartic, anthelmintic and other beneficial aspects to treat diseases, however, hellebores have also been known for their adverse and poisonous aspects. It is also because of their cytotoxic aspect that these species have also been explored as alternative approaches to cancer treatment and are mainly reported as sporadic patient cases in literature. In this study, we first focused on the phytochemical characterisation of Helleborus odorus subsp. cyclophyllus combining biochemical assays and a detailed characterisation of its antioxidant and antibacterial properties. Furthermore, regarding its toxic potential, we explored the cytotoxic toxic properties and the mechanisms of toxicity mediated effects using in vitro cell systems primary human aortic endothelial cells (HAECs). HAECs are useful for studying vascular diseases such as thrombosis, atherosclerosis, and hypertension as well as for stent-graft compatibility testing and within the 3Rs principles, avoiding animals in these studies. Results showed the cytotoxic and reactive oxygen species potential of Helleborus extract in dose and time dependent manner. Further investigation (not shown here) revealed more mechanistic effects relevant to inhibition of proliferation.

Contact: https://www.researchgate.net/profile/Anna-Michalaki

Related

The Beyond Animal Testing Index
Projects and initiatives

The Beyond Animal Testing Index

The Beyond Animal Testing Index (BATI) was designed after the Access to Medicine Index with the aim to be a transparent, objective and independent benchmark that provide public research organisations and their stakeholders insight in what efforts and contributions they make in the transition to animal free innovation and to provide organisations incentive to learn from and inspire each other with regard to the implementation of research practices without the use of animals for the benefit of science.
02:0011 days ago
Transition beyond animal welfare
Expert interviews

Transition beyond animal welfare

This video explains what the programme TPI (Transition Programme for Innovation without the use of animals) is about.
02:3925 days ago
SCREENED
Projects and initiatives

SCREENED

The European collaborative project SCREENED aims to develop three-dimensional (3D) cell-based in vitro tests to better characterize the effects of endocrine disruptors (EDs) on thyroid gland function. This method will overcome the limitations of existing tests, being more sensitive at low doses of exposure to chemicals, and enabling the prediction of their toxicity on human health in a sex-specific manner. The ambition of the SCREENED project is that these new 3D in vitro tests, as well as the increased knowledge about adverse reactions after exposure to EDs, will be used for regulatory purposes, ultimately to improve human health.
02:2125 days ago
Stichting Proefdiervrij: Collaboration is key
Expert interviews
HealthInnovationPolicy

Stichting Proefdiervrij: Collaboration is key

At Stichting Proefdiervrij (the Dutch society for the replacement of animal testing) we believe that collaboration is essential for the development and implementation of animal-free models. In this video we introduce a few of the ways in which we, as an NGO, collaborate with researchers to reach our goal: the complete replacement of all test on animals
02:0745 days ago